Norbrook Laboratories Receives FDA Approval For Hexasol Injection

 Resize text         Printer-friendly version of this article Printer-friendly version of this article

Norbrook Laboratories Ltd. announced the introduction of Hexasol Injection, which combines the long-acting antibiotic oxytetracycline (active ingredient in Noromycin 300 LA and 300 PRO LA) and the non-steroidal anti-inflammatory drug (NSAID) flunixin meglumine in one convenient dose. 

Hexasol Injection is indicated for the treatment of bacterial pneumonia associated with Pasteurella spp. and for the control of associated pyrexia (fever) in beef and non-lactating dairy cattle.

The duel-action formulation of Hexasol Injection offers veterinarians and cattle producers "a practical choice when combined antibiotic and antipyretic action is indicated," the company says. Key attributes of Hexasol Injection include "proven safe and effective ingredients, the convenience of a SQ or IM dosing option and a relatively short withdrawal time prior to slaughter of 21 days." 

Hexasol Injection is available by prescription only. 

Source: Norbrook Laboratories news release



Comments (0) Leave a comment 

Name
e-Mail (required)
Location

Comment:

characters left


RX7320

When moving hay to feed dairy cows, farmers are seeking a versatile tractor. KITOI’s new Tier 4 RX series tractors ... Read More

View all Products in this segment

View All Buyers Guides

)
Feedback Form
Leads to Insight